Latest News

STAT Plus: Pharmalittle: More companies recall heartburn tablets; Merck’s Keytruda wins another cancer approval

Top of the morning to you, and a fine one, it is, thanks to clear skies and refreshingly cool temperatures enveloping the Pharmalot campus. Our short person has been deposited at the local schoolhouse for another day of learning and our mascot is quietly snoozing in his corner. All of which is to say that we can now fire up the coffee kettle, brew a cup of stimulation, and dig in for another busy day. No doubt, you may be equally busy. So to help you along, here are a few tidbits. Hope all goes well today. You deserve it.

The Food and Drug Administration announced that Denton Pharma and Appco Pharma are voluntarily recalling batches of ranitidine heartburn tablets and Mylan (MYL) is voluntarily recalling lots of nizatidine heartburn tablets in the U.S. due to traces of NDMA, a possible carcinogen. The agency has not found evidence the medicines, including Zantac, form NDMA in patient stomachs or small intestines, but has previously indicated some contain higher than acceptable levels and asked manufacturers to voluntarily withdraw those pills.

Continue to STAT Plus to read the full story…

Source link

Related posts

Teens with more equitable gender attitudes have lower odds of reporting violent behaviors


Faith-based approach to changing lifestyle lowers blood pressure


Physitrack launches enterprise-focused offerings for its digital physical therapy platform


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy